DE602004029705D1 - 5,7-diaminopyrazoloä4,3-düpyrimidine mit pde-5-hemmender wirkung - Google Patents

5,7-diaminopyrazoloä4,3-düpyrimidine mit pde-5-hemmender wirkung

Info

Publication number
DE602004029705D1
DE602004029705D1 DE602004029705T DE602004029705T DE602004029705D1 DE 602004029705 D1 DE602004029705 D1 DE 602004029705D1 DE 602004029705 T DE602004029705 T DE 602004029705T DE 602004029705 T DE602004029705 T DE 602004029705T DE 602004029705 D1 DE602004029705 D1 DE 602004029705D1
Authority
DE
Germany
Prior art keywords
hemmender
düpyrimidine
pde
effect
hemmender effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004029705T
Other languages
English (en)
Inventor
Andrew Simon Bell
David Graham Brown
Kevin Neil Dack
David Nathan A Fox
Ian Roger Marsh
Andrew Ian Morrell
Michael John Palmer
Carol Ann Winslow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd
Pfizer Inc
Original Assignee
Pfizer Ltd
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd, Pfizer Inc filed Critical Pfizer Ltd
Publication of DE602004029705D1 publication Critical patent/DE602004029705D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials
DE602004029705T 2003-11-24 2004-11-12 5,7-diaminopyrazoloä4,3-düpyrimidine mit pde-5-hemmender wirkung Active DE602004029705D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0327319.0A GB0327319D0 (en) 2003-11-24 2003-11-24 Novel pharmaceuticals
PCT/IB2004/003747 WO2005049616A1 (en) 2003-11-24 2004-11-12 5,7-DIAMINOPYRAZOLO [4,3-d] PYRIMIDINES WITH PDE-5 INHIBITING ACTIVITY

Publications (1)

Publication Number Publication Date
DE602004029705D1 true DE602004029705D1 (de) 2010-12-02

Family

ID=29764364

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004029705T Active DE602004029705D1 (de) 2003-11-24 2004-11-12 5,7-diaminopyrazoloä4,3-düpyrimidine mit pde-5-hemmender wirkung

Country Status (44)

Country Link
EP (1) EP1689751B1 (de)
JP (1) JP4056015B2 (de)
KR (2) KR100893999B1 (de)
CN (4) CN1882591B (de)
AP (1) AP2227A (de)
AR (1) AR046711A1 (de)
AT (1) ATE485297T1 (de)
AU (1) AU2004290643B2 (de)
BR (1) BRPI0416869A (de)
CA (1) CA2546987C (de)
CR (1) CR8416A (de)
CY (1) CY1110933T1 (de)
DE (1) DE602004029705D1 (de)
DK (1) DK1689751T3 (de)
EA (1) EA011772B1 (de)
EC (1) ECSP066580A (de)
ES (1) ES2351622T3 (de)
GB (1) GB0327319D0 (de)
GE (1) GEP20084528B (de)
HK (2) HK1099286A1 (de)
HR (1) HRP20100651T1 (de)
IL (1) IL175433A (de)
IS (1) IS8406A (de)
MA (1) MA28172A1 (de)
ME (1) ME01216B (de)
MX (1) MXPA06005914A (de)
MY (1) MY140872A (de)
NL (1) NL1027568C2 (de)
NO (1) NO336526B1 (de)
NZ (1) NZ548097A (de)
OA (1) OA13289A (de)
PA (1) PA8617701A1 (de)
PE (1) PE20051061A1 (de)
PL (1) PL1689751T3 (de)
PT (1) PT1689751E (de)
RS (1) RS51556B (de)
SG (1) SG133614A1 (de)
SI (1) SI1689751T1 (de)
TN (1) TNSN06154A1 (de)
TW (1) TWI265031B (de)
UA (1) UA81994C2 (de)
UY (1) UY28625A1 (de)
WO (1) WO2005049616A1 (de)
ZA (1) ZA200602899B (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005286648A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
EP1830837B1 (de) 2004-09-20 2013-09-04 Xenon Pharmaceuticals Inc. Heterozyklische derivate zur behandlung von durch stearoyl-coa-desaturase-enzymen verursachte krankheiten
AR051090A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
AR051094A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
BRPI0515482A (pt) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos e seus usos como agentes terapêuticos
AU2005286728A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
MX2007003325A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores estearoil-coa-desaturasa.
EP1809632A2 (de) * 2004-10-28 2007-07-25 Pharmacia & Upjohn Company LLC Als pde-5-inhibitoren geeignetepyrazolo[4,3-d]pyrimidinderivate
PL1881985T3 (pl) * 2005-05-12 2011-05-31 Pfizer Bezwodne krystaliczne postacie N-[1-(2-etoksyetylo)-5-(N-etylo-N-metyloamino)-7-(4-metylopirydyn-2-yloamino)-1H-pirazolo[4,3-d]pirymidyno-3-karbonylo]metano-sulfonoamidu
JP2009513563A (ja) 2005-06-03 2009-04-02 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトのステアロイル−ＣｏＡデサチュラーゼ阻害剤としてのアミノチアゾール誘導体
NL1029244C2 (nl) * 2005-06-10 2006-12-12 Ronald Silfried Marlin Middel ter vergroting van het mannelijk geslachtsorgaan.
DE102005050377A1 (de) * 2005-10-21 2007-04-26 Bayer Healthcare Ag Heterocyclische Verbindungen und ihre Verwendung
NL2000291C2 (nl) 2005-11-10 2009-02-17 Pfizer Prod Inc 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
CA2633035C (en) 2005-12-15 2016-05-10 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
EP1820502A1 (de) * 2006-02-10 2007-08-22 Laboratorios Del Dr. Esteve, S.A. Wirkstoffzusammensetzungen enthaltend Azolycarbinolderivate
WO2007113243A2 (en) * 2006-03-31 2007-10-11 Investigación Y Clínica Andrológicas S.L. Use of pde 5 inhibitors for the treatment of overactive bladder
WO2008132589A1 (en) * 2007-05-01 2008-11-06 Pfizer Limited Combinations comprising pregabalin
WO2009050554A2 (en) * 2007-10-19 2009-04-23 Pfizer Inc. Treatment of central nervous system disorders
DE102008063992A1 (de) * 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
WO2012131539A1 (en) 2011-03-31 2012-10-04 Pfizer Inc. Novel bicyclic pyridinones
WO2012172449A1 (en) 2011-06-13 2012-12-20 Pfizer Inc. Lactams as beta secretase inhibitors
ES2605565T3 (es) 2011-08-31 2017-03-15 Pfizer Inc Compuestos de hexahidropirano [3,4-D][1,3]tiazin-2-amina
WO2013164730A1 (en) 2012-05-04 2013-11-07 Pfizer Inc. Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin- 2 -amine compounds as inhibitors of app, bace1 and bace 2.
JP2015529239A (ja) 2012-09-20 2015-10-05 ファイザー・インク アルキル置換ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
CA2893256A1 (en) 2012-12-11 2014-06-19 Pfizer Inc. Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
CA2893333C (en) 2012-12-19 2017-10-24 Pfizer Inc. Carbocyclic-and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
EP2956458B1 (de) 2013-02-13 2017-08-09 Pfizer Inc Heteroarylsubstituierte hexahydropyrano[3,4-d][1,3]thiazin-2-amin-verbindungen
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
KR20150119370A (ko) 2013-02-19 2015-10-23 화이자 인코포레이티드 Cns 장애 및 다른 장애의 치료를 위한 pde4 동종효소의 억제제로서의 아자벤즈이미다졸 화합물
CA2925743C (en) 2013-10-04 2018-03-06 Pfizer Inc. Novel bicyclic pyridinones as gamma-secretase modulators
WO2015091428A1 (en) * 2013-12-20 2015-06-25 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
AP2016009465A0 (en) 2014-04-01 2016-09-30 Pfizer Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators
CN106132953B (zh) * 2014-04-04 2019-03-22 H.隆德贝克有限公司 作为pde1抑制剂的卤化的喹唑啉-thf-胺
WO2015155626A1 (en) 2014-04-10 2015-10-15 Pfizer Inc. 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
JP6713982B2 (ja) 2014-07-24 2020-06-24 ファイザー・インク ピラゾロピリミジン化合物
PE20170295A1 (es) 2014-08-06 2017-03-30 Pfizer Compuestos de imidazopiridazina
JP2017537118A (ja) * 2014-12-08 2017-12-14 ヤンセン・サイエンシズ・アイルランド・ユーシー Ｒｓウイルス（ｒｓｖ）複製の阻害活性を有するピペリジン置換ピラゾロ［１，５−ａ］ピリミジン誘導体
AU2016214102B2 (en) 2015-02-03 2018-09-27 Pfizer Inc. Novel cyclopropabenzofuranyl pyridopyrazinediones
CR20170572A (es) 2015-06-17 2018-03-20 Pfizer Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
JP2018534251A (ja) 2015-09-24 2018-11-22 ファイザー・インク Ｂａｃｅ阻害剤として有用なｎ−［２−（３−アミノ−２，５−ジメチル−１，１−ジオキシド−５，６−ジヒドロ−２ｈ−１，２，４−チアジアジン−５−イル）−１，３−チアゾール−４−イル］アミド
AU2016325665A1 (en) 2015-09-24 2018-03-08 Pfizer Inc. N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides
JP2018531924A (ja) 2015-09-24 2018-11-01 ファイザー・インク テトラヒドロピラノ［３，４−ｄ］［１，３］オキサジン誘導体、およびｂａｃｅ阻害剤としてのその使用
ES2775674T3 (es) 2016-02-23 2020-07-27 Pfizer Compuestos de 6,7-dihidro-5H-pirazolo[5,1-b][1,3]oxazina-2-carboxamida
EP3872078A1 (de) 2016-07-01 2021-09-01 Pfizer Inc. 5,7-dihydro-pyrrolo-pyridin-derivate zur verwendung für die behandlung von depression, angst oder panikstörungen
DK3642202T3 (da) 2017-06-22 2023-01-30 Pfizer Dihydro-pyrrolo-pyridin-derivater
ES2942837T3 (es) 2018-03-23 2023-06-07 Pfizer Derivados de azaespiro piperazina
BR112020024700A2 (pt) 2018-06-04 2021-03-02 Exscientia Ltd compostos de pirazolopirimidina como antagonistas receptores de adenosina
AU2019325656A1 (en) * 2018-08-24 2021-03-11 Terns, Inc. Thyroid hormone receptor beta agonist compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW370529B (en) * 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
JP2002528456A (ja) * 1998-10-23 2002-09-03 ファイザー・インク 性的機能障害の処置のためのピラゾロピリミジノン系ｃＧＭＰ阻害薬
GB9823102D0 (en) * 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
DE10031236A1 (de) * 2000-06-27 2002-01-10 Qiagen Gmbh Verwendung von Carbonsäuren und anderen Additiven in Kombination mit kationischen Verbindungen zur Stabilisierung von Nukleinsäuren in biologischen Materialien
DE10031584A1 (de) * 2000-06-29 2002-01-10 Merck Patent Gmbh 5-Aminoalkyl-pyrazolo[4,3-d]pyrimidine
DE60237425D1 (de) * 2002-03-28 2010-10-07 Univerzita Palackeho V Olomouc PyrazoloÄ4,3-dÜpyrimidine, Verfahren zu ihrer Herstellung und therapeutische Anwendung
EP1620437B1 (de) * 2003-04-29 2009-06-17 Pfizer Limited 5,7-diaminopyrazolo¬4,3-d pyrimidine zur verwendung in der behandlung von bluthochdruck

Also Published As

Publication number Publication date
SG133614A1 (en) 2007-07-30
NO336526B1 (no) 2015-09-21
CA2546987A1 (en) 2005-06-02
UA81994C2 (en) 2008-02-25
HRP20100651T1 (hr) 2011-01-31
KR100848216B1 (ko) 2008-07-24
EA200600677A1 (ru) 2006-12-29
KR20070026334A (ko) 2007-03-08
CR8416A (es) 2006-11-15
CN101647802A (zh) 2010-02-17
KR20080052666A (ko) 2008-06-11
WO2005049616A8 (en) 2006-06-01
MXPA06005914A (es) 2006-06-27
IL175433A0 (en) 2006-09-05
EP1689751B1 (de) 2010-10-20
CN101362764B (zh) 2011-04-20
IS8406A (is) 2006-04-10
AP2227A (en) 2011-03-29
HK1099286A1 (en) 2007-08-10
PE20051061A1 (es) 2005-12-12
JP2007512314A (ja) 2007-05-17
CN101362765A (zh) 2009-02-11
TW200520758A (en) 2005-07-01
ATE485297T1 (de) 2010-11-15
CN1882591A (zh) 2006-12-20
NZ548097A (en) 2008-12-24
CA2546987C (en) 2009-05-12
NL1027568A1 (nl) 2005-05-26
MY140872A (en) 2010-01-29
AR046711A1 (es) 2005-12-21
AU2004290643A1 (en) 2005-06-02
JP4056015B2 (ja) 2008-03-05
NL1027568C2 (nl) 2005-11-30
GB0327319D0 (en) 2003-12-24
NO20062950L (no) 2006-08-23
TWI265031B (en) 2006-11-01
IL175433A (en) 2011-08-31
ZA200602899B (en) 2007-07-25
ME01216B (me) 2013-03-20
EP1689751A1 (de) 2006-08-16
AU2004290643B2 (en) 2008-08-07
CN101362764A (zh) 2009-02-11
SI1689751T1 (sl) 2011-01-31
KR100893999B1 (ko) 2009-04-20
GEP20084528B (en) 2008-11-10
CY1110933T1 (el) 2015-06-10
CN1882591B (zh) 2011-08-10
CN101362765B (zh) 2011-02-02
ECSP066580A (es) 2006-12-20
PA8617701A1 (es) 2005-08-04
UY28625A1 (es) 2005-06-30
DK1689751T3 (da) 2011-01-17
MA28172A1 (fr) 2006-09-01
RS51556B (en) 2011-06-30
BRPI0416869A (pt) 2007-03-27
AP2006003591A0 (en) 2006-04-30
ES2351622T3 (es) 2011-02-08
WO2005049616A1 (en) 2005-06-02
HK1128917A1 (en) 2009-11-13
EA011772B1 (ru) 2009-06-30
TNSN06154A1 (fr) 2007-11-15
OA13289A (en) 2007-01-31
PL1689751T3 (pl) 2011-03-31
PT1689751E (pt) 2010-11-29

Similar Documents

Publication Publication Date Title
DE602004029705D1 (de) 5,7-diaminopyrazoloä4,3-düpyrimidine mit pde-5-hemmender wirkung
CY2014041I1 (el) 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια
DE60332125D1 (de) Indole mit antidiabetischer wirkung
NO20055568D0 (no) Substituerte 1,4-diazepiner og anvendelser derav
ATE509010T1 (de) 2, 4, 6-phenylsubstituierte cyclische ketoenole
ATE390423T1 (de) Benzoazolylpiperazinderivate mit vr1- antagonistischer wirkung
ATE402152T1 (de) Hiv-inhibierende1,2,4-triazine
ATE432008T1 (de) Repellentmittel
NO20032883L (no) Bolgekraftverk.
DE602004006169D1 (de) Substituierte 8'-pyri(mi)dinyl-dihydrospiro-äcycloalkylaminü-pyrimidoä1,2aüpyrimidin-6-onderivate
DE502004011333D1 (de) Polyalkenamine mit verbesserten anwendungseigenschaften
DE602004021572D1 (de) SUBSTITUIERTE 8-PERFLUORO-6,7,8,9-TETRAHYDROPYRIMIDOi1,2-A PYRIMIDIN-4-ON-DERIVATE
DE60305332D1 (de) IMIDAZOi1,2-AöPYRIDINE
ATE446750T1 (de) 3-cyano-chinolin-derivate mit antiproliferativer wirkung
ATE361282T1 (de) Indazol-aminoacetonitrilderivate mit pestizider wirkung
DE602004010385D1 (de) 3,4-disubstituierte 1,2,3,4-tetrahydropyridinderivate
DE602004027792D1 (de) Indazolamide mit analgetischer wirkung
DE60315984D1 (de) Substituierte benzisoxazolsulfonamide mit breitbändiger hiv-protease hemmender wirkung
ATE504290T1 (de) Zusammensetzungen mit neramexan
DE602004027594D1 (de) Triac
DE602004017199D1 (de) Silikonverbindungen mit mikrobizider wirkung
NO20044405L (no) Neurotensinaktive 2,3-diaryl-pyrazolidin derivater
DE60232170D1 (de) Thieno-(1,3)-oxazin-4-one mit lipase inhibierender wirkung
ATE504278T1 (de) Hosenförmiger artikel mit verbesserter passform
ES1055830Y (es) Mosquitera.